TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
Filed with ASX · · 3 pages · English
Story so far
Earlier from Immutep
- Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
- New investigator-initiated Phase II trial for Efti
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
- Appendix 4E & 2025 Full Year Statutory Accounts
- Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
Later from Immutep
- Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
- Successful Completion of FDA Project Optimus Requirements
- Immutep Announces Successful Completion of FDA Project Optimus Requirements
- Improved ORR in First Line NSCLC - presented at ESMO 2025
- Primary Endpoint Met in STS Trial - presented at ESMO 2025
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep